Everest Medicines signs a letter of intent with Haisen Biopharmaceuticals (Asia) Limited

Everest Medicines (HKEX 1952.HK, hereinafter referred to as 'the Company'), a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing, and commercialization, announced today that the Company has signed a letter of intent with Haisen Biopharmaceuticals (Asia) Limited to acquire all the equity of its wholly-owned subsidiary, Haisen Biopharmaceuticals (Singapore) Pte. Ltd. If this potential transaction is successfully completed, it will enrich the Company's existing product pipeline, expand its business scale in the Asia-Pacific region, further advance Everest Medicines' strategic layout in the Asian market, and accelerate the creation of an innovative drug commercialization platform covering the Asia-Pacific region.

According to the letter of intent, Everest Medicines will pay a refundable deposit totaling RMB 200 million to Haisen Biopharmaceuticals (Asia) Limited. This deposit will be paid within five business days after signing the letter of intent and can be converted into part of the future acquisition consideration as agreed by both parties or refunded to a designated account under specific conditions. Meanwhile, Haisen Biopharmaceuticals (Asia) Limited will authorize the management of Haisen Biopharmaceuticals (Singapore) Pte. Ltd. to allow Everest Medicines to conduct due diligence. Both parties have agreed on a six-month exclusive negotiation period to advance the potential acquisition.

Haisen Biopharmaceuticals (Singapore) Pte. Ltd. focuses on the commercialization of prescription drugs in chronic diseases and acute critical care areas (especially cardiovascular and metabolic segments). It holds asset rights for 14 branded products in the chronic disease field across multiple countries and regions in the Asia-Pacific, including marketing authorization holder (MAH) rights, trademarks, and extensive commercialization rights. The company has established an innovative pan-Asia-Pacific commercialization platform capable of value realization, benefiting tens of millions of chronic disease patients in the Asia-Pacific region.

Currently, Southeast Asia has a population of approximately 600 million, and there remains significant unmet medical needs in the field of chronic disease management, offering tremendous market potential. Over recent years, Everest Medicines has continued to deepen its strategic layout in the chronic disease sector, with its product pipeline focusing on CKM (cardiovascular, kidney, and metabolic) treatment areas. There is high potential for efficient synergy between these efforts and Haisen Biopharmaceuticals (Singapore) Pte. Ltd.'s product portfolio and commercialization capabilities.

Everest Medicines is committed to becoming a benchmark for innovative drug commercialization platforms in the Asia-Pacific region and an internationally leading biopharmaceutical enterprise. Over the past three years, the company has successfully commercialized Nefecon®, a blockbuster product in the nephrology field, establishing itself as a leader in the domestic chronic disease innovative drug commercialization platform. Currently, the company's commercialized products—Nefecon®, Vuseltinib®, and Ecallantide®—are gradually receiving new drug approval applications in Asian territories outside mainland China and entering local reimbursement coverage. If this acquisition is successfully completed, the company will take a key step in its global strategic layout. Not only will it potentially accelerate the overseas commercialization of existing products, leading to rapid growth in overseas sales revenue, but it will also expand its international commercialization footprint at 'Everest speed.'

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on innovative drug research and development, clinical development, manufacturing, and commercialization, committed to addressing unmet medical needs in global markets. The management team of Everest Medicines possesses deep expertise and extensive experience from leading pharmaceutical enterprises in China and globally. The company owns a commercial-scale global production base in Jiashan, Zhejiang, constructed strictly in accordance with the GMP requirements of the National Medical Products Administration (NMPA) and the European Medicines Agency (EMA), as well as the WHO PQ standards.

The company focuses on treatment areas such as autoimmune diseases, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. It has built a commercialization platform that integrates an omnichannel commercial system with the ability to manage the entire drug lifecycle. Based on its self-developed mRNA platform, which holds global rights, the company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines. At the same time, it is expanding its R&D capabilities by introducing promising platforms and fostering ecosystem incubation, while strengthening its global footprint and accelerating international development. For more information, please visit the company's official website: www.everestmedicines.com.

About Haisen Biopharmaceuticals (Asia) Limited and Haisen Biopharmaceuticals (Singapore) Limited

Haisen Biopharmaceuticals (Asia) Limited is a company incorporated in the Cayman Islands, mainly engaged in investment holding.

Haisen Biopharmaceuticals (Singapore) Limited is a company incorporated in Singapore, primarily focused on the commercialization of prescription drugs in chronic diseases and critical care areas, particularly within cardiovascular and metabolic segments. The company holds asset rights to 14 branded products in the chronic disease space across multiple countries in the Asia-Pacific region, including Marketing Authorization Holder (MAH) rights, trademarks, and extensive commercialization rights.

Forward-Looking Statements

This press release may contain certain forward-looking statements based on the company’s or management’s current views, beliefs, and expectations regarding the company’s business operations and financial condition at the time of making the statements. These statements may include terms such as “will,” “expect,” “forecast,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “confident,” and other similar expressions. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the company’s control and difficult to predict. Therefore, actual results may differ materially from those implied in the forward-looking statements due to various factors and assumptions, including changes and developments in our business, competitive environment, political, economic, legal, and social conditions. Neither the company nor its subsidiaries, directors, officers, advisors, or agents assume any obligation to update the forward-looking statements contained in this release to reflect subsequent information, future events, or circumstances unless required by law.

9719 Views